



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

31st May 2018

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Subject – Press Release in connection with Audited (Standalone) Financials for the quarter and year ended March 31, 2018.

Dear Sir/Madam,

Please find enclosed herewith the copy of Press Release in connection with the Audited (Standalone) Financials for the quarter and year ended March 31, 2018.

Thanking You
Yours faithfully,

For Nath Bio-Genes (India) Limited

Devinder Khurana
Chief Financial Officer

Encl: As above

- Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com
- 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

NATH
GROUP

Standalone FY18 Results

Total Income ₹ 192.59 Crores, a growth of 13% Y-o-Y basis

EBITDA grew by 40% Y-o-Y to ₹ 41.31 Crores

Cash PAT grew by 57% Y-o-Y to ₹ 30.37 Crores

Aurangabad, May 18, 2018: Nath Bio-Genes (India) Limited (“Company”), a fast growing Seeds Company, producing, processing and marketing Field Crop and Vegetable Crop Seeds and Plant Nutrient Supplement to the farming community through a PAN India network of distributors announced its Audited Financial (Standalone & Consolidated) results for the quarter and full year ended March 31, 2018. The Financial Results are as per Ind-AS.

Key Wins

- The company has set up a vegetable vertical to provide impetus to vegetable sales.
- The R & D Center, under the leadership of Dr. Ish Chopra is under process of being set up.
- The company plan of enhancing vegetable sales is shaping up well.
- The PNS segment is also providing the right growth impetus to the sales.
- The company plan to balance Kharif and Rabi crops is shaping well with Rabi sales in FY 18 being 40% of the total sales.

Key Financial Highlights on Standalone basis are as follows:

Nath Bio-Genes (India)			
Particulars (₹ Crs)	FY18	FY17	Y-o-Y%
Total Income	192.59	170.38	13.04%
EBITDA	41.31	29.51	40.00%
Margin (%)	21.47%	17.32%	
Cash PAT	30.36	19.31	57.25%

Performance highlights for FY2017-18

Total Income for FY18 grew by 13.04% to ₹192.59 Crores as compared to ₹169.87 Crores in FY17. The growth is attributed to a 50% growth in vegetable and Plant Nutrient (PNS) segment as also reasonable growth in Cotton, Paddy and Mustard seed sale. GST implementation in FY18, did not have any significant effect on the company operations, apart from the implementation hassles.

EBITDA for FY18 grew by a healthy 40.00% to ₹41.31 Crores as compared to ₹29.51 Crores in FY17. EBITDA margin stood at 21.45% for FY18.

Finance cost for FY18 remained steady at ₹10.35 Crores as compared to ₹9.66 Crores in FY17 on absolute basis. However, the company repaid all its long-term loans raised from banks and institutions in FY



18. The interest cost is bound to reduce in FY 19, pursuant to the reduction in loans. The positive impact in terms of lower finance costs is likely to be visible in FY19 financials.

Depreciation and amortisation expense for FY18 stood at ₹0.95 Crores as compared to ₹3.03 Crores in FY17. While the tangible annual depreciation for FY18 vis-à-vis FY17 stood at similar levels, amortization of intangibles of FY 17 was completed and hence the overall depreciation reduced.

Total Comprehensive Income for FY18 grew by a very healthy 80.68% to ₹29.42 Crores from ₹16.28 Crores. The Profitability was enhanced primarily due to increased sales, improved product mix contribution and reduced expenses.

Cash PAT for FY18 grew by 57.25% to ₹30.37 Crores as compared to ₹19.31 Crores in FY17.

Core Assets were valued at fair value and accounted for in the books of the company pursuant to the Ind AS guidelines.

During Q4 FY18 our **Credit Rating was upgraded by Ratings Agency**, Credit rating India Limited (CRISIL). Our Long-Term Bank facilities have been upgraded to BBB (Stable)

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward- looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information please visit www.nathbiogenes.com

Company
Nath Bio-Genes (India) Limited CIN No: L01110MH1993PLC072842
Name: Mr. Devinder Khurana Designation – CFO Email id: mail@khurana.co.in

